SCHEMBL805163

SCHEMBL805163

CCc1ccc(-c2ccc(Cl)cc2Cl)o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.46
▸ MAPT P10636 7/20 0.46
▸ NPC1 O15118 5/20 0.46
▸ RAB9A P51151 5/20 0.46
▸ PKM P14618 1/20 0.46
▸ ALOX15 P16050 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ SMN1; SMN2 Q16637 5/20 0.45
▸ POLB P06746 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ HPGD P15428 6/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ ESR1 P03372 1/20 0.44
▸ MAPK1 P28482 4/20 0.44
▸ LMNA P02545 3/20 0.44
▸ BLM P54132 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL805123 0.86 HSD17B2 (0.52) ALDH1A1MAPTPKMALOX15USP2
SCHEMBL13826533 0.83 ALDH1A1 (0.49) ALDH1A1MAPTNPC1RAB9APKM
SCHEMBL27990140 0.83 NPC1 (0.46) ALDH1A1MAPTNPC1RAB9APKM
SCHEMBL13719298 0.82 MAPT (0.45) ALDH1A1MAPTNPC1RAB9APKM
SCHEMBL13749573 0.79 LMNA (0.51) ALDH1A1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL27990410 0.77 HTT (0.46) ALDH1A1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15996807 0.77 MAPT (0.50) ALDH1A1MAPTNPC1RAB9APKM
SCHEMBL29288167 0.75 HSD17B2 (0.41) ALDH1A1MAPTNPC1RAB9APKM
SCHEMBL29288168 0.75 HSD17B2 (0.41) ALDH1A1MAPTNPC1RAB9APKM
SCHEMBL21119020 0.75 MAPT (0.56) ALDH1A1MAPTNPC1RAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071652-A1 Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof CORNERSTONE THERAPEUTICS, INC. (US) 2012-03-22 — — US disclosed
US-7943622-B2 Piperazines, pharmaceutical compositions and methods of use thereof CORNERSTONE THERAPEUTICS, INC. (US) 2011-05-17 — — US disclosed
US-7579479-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-25 — — US disclosed
US-20080051415-A1 Novel piperazines, pharmaceutical compositions and methods of use thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2008-02-28 — — US disclosed
US-7241780-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOLS-MYERS SQUIBB COMPANY (US) 2007-07-10 — — US disclosed
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071652-A1 Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof CHRNA7, CHRNA5, CHRNA2 ALDH1A1 1032/4885MAPT 2141/4885NPC1 1706/4885
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, ACACA ALDH1A1 1055/4885MAPT 4848/4885NPC1 361/4885
US-20080051415-A1 Novel piperazines, pharmaceutical compositions and methods of use thereof CHRNA7, CHRNA5, CHRNA2 ALDH1A1 1032/4885MAPT 2141/4885NPC1 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback